The nation of Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (£272m) spanning five years because of the United States' demand for confidential data.
The decision came to light following a official document from December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "lopsided".
A government representative later stated that the United States was demanding access to health data for research and commercial purposes while was not willing to guarantee the benefits from any future medical innovations.
"We are forced to start the difficult and regrettable task of winding down our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged further negotiations to reach a agreement acceptable to all parties so the country's vital HIV programme can proceed.
Wider Background
This rejection follows a comparable situation in neighbouring Kenya, where a court blocked a similar deal with the US after concerns were filed about the safety of citizens' health data.
After returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government deals to boost transparency and accountability.
Based on statements, Sixteen nations in Africa have so far agreed to these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration could have provided immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on HIV treatment via US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its biological resources and data over an extended period, with no equivalent guarantee of access to any medical innovations – like new medicines or tests – that could result from that shared data," Mangwana explained.
"Put simply, our nation would provide the basic resources for scientific discovery with no certainty that the end products would be accessible to our people should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending systems already established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This mechanism is intended to ensure that when a country contributes its data, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage ongoing discussions with our US partners on how future co-operation could be arranged in a way that respects the independence and interests of each country."
Health Experts Reaction
A leading public health body stated it understood the official position, but recommended that negotiations must proceed since much of the country's HIV programmes were funded by foreign aid.
"Where specific concerns arise, such as those involving information security or agreement terms, these can often be resolved via technical clarification and mutually agreed protections," it added.
This impasse emphasises the ongoing tensions between accepting crucial foreign assistance and safeguarding local interests in an increasingly data-driven world.